Any number of companies—including private equity firms—might be interested in ENTA for the financials alone. Among HCV players, NVS would enjoy a strategic benefit to owning ENTA if the Alisporvir + EDP-239 combination pans out.
To re-iterate, there are no legal impediments I'm aware of that would preclude a buyout of ENTA by someone other than ABBV.
Market Data 
Markets 
AI
